Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Cancer Discov. 2013 Aug 21;3(11):10.1158/2159-8290.CD-13-0397. doi: 10.1158/2159-8290.CD-13-0397

Figure 1. Atg7 deletion blocks autophagy in a mouse model of brafV600E–driven lung tumorigenesis.

Figure 1

A. Representative IHC for ATG7 and Surfactant Protein C at 7 (BrafV600E/+; Atg7 +/+ and BrafV600E/+; Atg7−/−) post Cre. Quantification of these data is shown. IHC for ATG7 expression at late time points (20, 30 weeks) is provided in Figure S1. Scale bar= 10μm

B. Western blot analysis of LC3-I to LC3-II conversion, and assessment of p62 accumulation in BrafV600E/+; Atg7 +/+ and BrafV600E/+; Atg7−/− tumor lysates 10 weeks post Cre. Numbers refer to individual mice. A blank lane was intentionally included between the normal lung and tumor lysates. An additional Atg7 null tumor lysate was spliced out for aesthetic reasons.

C. Representative IHC staining of LC3 puncta in BrafV600E/+; Atg7 +/+ and BrafV600E/+; Atg7 −/− tumors 8 weeks post infection. Scale bar= 10μm. Arrows denote puncta. Note the absence of puncta and accumulation of diffuse staining in the Atg7 null tumors.